

<b>Table S1: Rheumatic diseases in Covid-19 patients</b>		
<b>Disease</b>	<b>Total (n=122)</b>	<b>Exitus (n=14)</b>
Rheumatoid arthritis	41	3
Spondyloarthritis	24	1
SLE	13	3
Psoriatic Arthritis	13	0
Polymyalgia rheumatica	8	2
Giant cell arteritis	4	3
Systemic sclerosis	2	0
Undifferentiated connective tissue disease	3	0
Undifferentiated arthritis	1	0
Behçet disease	2	0
Adult-onset Still disease	2	0
Juvenile idiopathic arthritis	2	0
MCTD	2	1
Primary Sjögren disease	1	0
Overlap disease†	1	1
ANCA-positive vasculitis	1	0
Sarcoidosis	1	0
Idiopathic uveitis	1	0

SLE: systemic lupus erythematosus; MCTD: mixed connective tissue disease

†Overlap syndrome featuring with systemic sclerosis, inflammatory myositis and anti-PL12 positive

<b>Variable</b>	<b>Exitus (n=14)</b>	<b>Survival (n=108)</b>	<b>p-value</b>
<b>Demographics</b>			
Female sex , n (%)	8 (57.1)	72 (66.6)	0.54
Age (mean $\pm$ SD),	76.2 $\pm$ 12.6	55.8 $\pm$ 15.3	<0.01
<b>Comorbidity</b>			
Hypertension	12 (85.7)	35 (32.4)	<0.01
Obesity	7 (50.0)	25 (23.1)	0.25
Pulmonar chronic disease	6 (42.8)	13 (12.0)	0.01
Cardiovascular disease	9 (64.2)	12 (11.1)	<0.01
Diabetes mellitus	1 (7.1)	13 (12.0)	0.34
Active smokers	1 (7.1)	6 (5.5)	0.62
Treatment with ACE/ARB, n (%)	6 (42.8)	27 (25.0)	0.18
Duration of rheumatic disease, years (mean $\pm$ SD)	8.3 $\pm$ 7.2	12.6 $\pm$ 9.4	0.42
<b>Concomitant rheumatological treatment, n (%)</b>			
Hydroxychloroquine	4 (28.5)	22 (20.3)	0.37
Glucocorticoids	11 (78.5)	37 (34.2)	<0.01
Prednisone dose >5 mg/d	9 (64.2)	30 (27.7)	0.01
sDMARDs	7 (50.0)	71 (65.7)	0.24
Methotrexate	5 (35.7)	48 (44.4)	0.57
Sulfasalazine	2 (14.2)	16 (14.8)	0.64
Azathioprine	1 (7.1)	1 (0.9)	0.22
Leflunomide	0 (0.0)	13 (12.0)	-
Cyclophosphamide	0 (0.0)	1 (0.9)	-

bDMARDs/tsDMARDs	1 (7.1)	40 (37.0)	0.03
AntiTNF	0 (0.0)	27 (25.0)	0.03
Rituximab	1 (7.1)	6 (5.5)	0.59
Abatacept	0 (0.0)	3 (2.7)	-
Sarilumab*	0 (0.0)	0 (0.0)	-
Tofacitinib	0 (0.0)	1 (0.9)	-
Baricitinib	0 (0.0)	1 (0.9)	-
Tocilizumab	0 (0.0)	1 (0.9)	-
Secukinumab	0 (0.0)	1 (0.9)	-
Pneumonia, n (%)	11 (100)†	54 (58.7)	<0.001
Time from disease onset to hospital admission, days (median IQR)	8 (5-15.2)	7 (4-10.5)	0.08
Covid-19 specific treatment, n (%)	10 (71.4)	58 (53.7)	0.27

ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker; cDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs; tsDMARDs: targeted synthetic disease-modifying antirheumatic drugs

\*One patient on double blind clinical trial with sarilumab vs placebo

†In two additional patients, there was no chest image performed, but featured with respiratory insufficiency and needed oxygen supply. In another patient, data regarding pneumonia or dyspnoea is missing.